1 |
Ju, Z.G., C.L. Liu, and Y.B. Yuan, Activities of Chalcone Synthase and Udpgal - Flavonoid-3-O-Glycosyltransferase in Relation to Anthocyanin Synthesis in Apple. Scientia Horticulturae, 1995;63(3-4):175-185.
DOI
|
2 |
Orlikova, B., et al., Dietary chalcones with chemopreventive and chemotherapeutic potential. Genes Nutr, 2011;6(2): 125-47.
DOI
|
3 |
Roughead, E.E., et al., Variation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective analysis of Large Healthcare Claims Databases in Six Countries. Drug Saf, 2015;38(9):823-31.
DOI
|
4 |
Govindan, J. and M. Evans, Pioglitazone in clinical practice: where are we now? Diabetes Ther, 2012;3(1):1-8.
DOI
|
5 |
Hsieh, C.T., et al., Synthesis of chalcone derivatives as potential anti-diabetic agents. Bioorganic & Medicinal Chemistry Letters, 2012;22(12):3912-3915.
DOI
|
6 |
Spiegelman, B.M., PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes, 1998;47(4):507-14.
DOI
|
7 |
Swaroop, J.J., D. Rajarajeswari, and J.N. Naidu, Association of TNF-alpha with insulin resistance in type 2 diabetes mellitus. Indian J Med Res, 2012;135:127-30.
DOI
|
8 |
Jain, R.G., K.D. Phelps, and P.H. Pekala, Tumor necrosis factor-alpha initiated signal transduction in 3T3-L1 adipocytes. J Cell Physiol, 1999; 179(1):58-66.
DOI
|
9 |
Ohnogi, H., et al., Six New Chalcones from Angelica keiskei Inducing Adiponectin Production in 3T3-L1 Adipocytes. Bioscience Biotechnology and Biochemistry, 2012;76(5): 961-966.
DOI
|
10 |
Lee da, Y., et al., A synthetic chalcone derivative, 2-hydroxy- 3',5,5'-trimethoxychalcone (DK-139), suppresses the TNF alpha-induced invasive capability of MDA-MB-231 human breast cancer cells by inhibiting NF-kappaB-mediated GRO alpha expression. Bioorg Med Chem Lett, 2016;26(1):203-8.
DOI
|
11 |
Meng, C.Q., et al., Discovery of novel heteroaryl-substituted chalcones as inhibitors of TNF-alpha-induced VCAM-1 expression. Bioorg Med Chem Lett, 2004;14(6):1513-7.
DOI
|
12 |
Sethi, J.K. and G.S. Hotamisligil, The role of TNF alpha in adipocyte metabolism. Seminars in Cell & Developmental Biology, 1999;10(1):19-29.
DOI
|
13 |
Lin, Y.M., et al., Chalcones and flavonoids as anti- tuberculosis agents. Bioorg Med Chem, 2002;10(8):2795-802.
DOI
|
14 |
Fogaca, T.B., et al., Apoptotic effect of chalcone derivatives of 2-acetylthiophene in human breast cancer cells. Pharmacological Reports, 2017;69(1):156-161.
DOI
|
15 |
Zou, C. and J. Shao, Role of adipocytokines in obesityassociated insulin resistance. J Nutr Biochem, 2008;19(5): 277-86.
DOI
|
16 |
Ferre, P., The biology of peroxisome proliferator - Activated receptors - Relationship with lipid metabolism and insulin sensitivity. Diabetes, 2004;53:S43-S50.
DOI
|
17 |
Iwaki, M., et al., Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes, 2003;52(7):1655-63.
DOI
|
18 |
Kamei, H., et al., Tumor cell growth suppression by chalcone (1,3-diphenyl-2-propen-1-one). Cancer Biotherapy and Radiopharmaceuticals, 1997;12(1):51-54.
DOI
|
19 |
Nowakowska, Z., A review of anti-infective and antiinflammatory chalcones. Eur J Med Chem, 2007;42(2): 125-37.
DOI
|
20 |
Yadav, V.R., et al., The role of chalcones in suppression of NF-kappaB-mediated inflammation and cancer. Int Immunopharmacol, 2011;11(3):295-309.
DOI
|
21 |
Kotronen, A., et al., Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology, 2008;135(1):122-30.
DOI
|
22 |
Wallia, A. and M.E. Molitch, Insulin Therapy for Type 2 Diabetes Mellitus. Jama-Journal of the American Medical Association, 2014;311(22):2315-2325.
DOI
|
23 |
Aberer, F., et al., Review of the Efficiency and Safety of a simple Insulin Dispensing Device (PaQ (R)) in Patients with Diabetes mellitus Type 2. Wiener Klinische Wochenschrift, 2015;127:S136-S136.
|
24 |
Andrade-Oliveira, V., N.O. Camara, and P.M. Moraes-Vieira, Adipokines as drug targets in diabetes and underlying disturbances. J Diabetes Res, 2015;2015:681612.
|
25 |
Rasouli, N., et al., Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. American Journal of Physiology-Endocrinology and Metabolism, 2006;290(1): E42-E46.
DOI
|
26 |
Hotamisligil, G.S., N.S. Shargill, and B.M. Spiegelman, Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science, 1993; 259(5091):87-91.
DOI
|
27 |
Pandey, M., D.J. Loskutoff, and F. Samad, Molecular mechanisms of tumor necrosis factor-alpha-mediated plasminogen activator inhibitor-1 expression in adipocytes. Faseb Journal, 2005;19(7):1317-+.
DOI
|
28 |
Kim, S.G., et al., Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome. Eur J Endocrinol, 2006;154(3):433-40.
DOI
|
29 |
Buras, J., et al., Troglitazone-induced changes in adiponectin do not affect endothelial function in diabetes. Obes Res, 2005;13(7):1167-74.
DOI
|